Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

NKTR

NEKTAR THERAPEUTICS

Pharmaceutical Preparations · SIC 2834CIK 906709Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$55.0M
Net Income FY2025
$(164.0M)
EPS (Basic, as reported)
$-9.73
Net Margin FY2025
-297.1%
ROE FY2025
-182.6%
Total Equity
$90.0M
Shares Out
34M
Business description

NEKTAR THERAPEUTICS — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 165 → 55 -11.5% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024⚑FY2025
Revenue1653081,19311515310292909855
Cost of revenue(30)(31)(24)(21)(19)(25)(22)(34)(31)0
Research & development(204)(268)(400)(435)(409)(400)(218)(114)(121)(117)
General & administrative(44)(52)(81)(99)(105)(123)(92)(77)(77)(69)
Total operating expenses(278)(367)(505)(555)(578)(548)(468)(354)(204)(195)
Operating income(113)(60)688(440)(425)(446)(376)(264)(105)(140)
Interest expense(22)(22)(22)(21)(7)00———
Interest & investment income—————37191510
Other income (expense), net(40)(36)(5)0(19)(77)11(13)(14)(15)
Pre-tax income(153)(96)683(440)(444)(523)(365)(276)(119)(164)
Income tax expense(1)(1)(1)(1)0(1)(3)000
Net income(154)(97)681(441)(444)(524)(368)(276)(119)(164)
EPS — basic($1.10)($0.62)$4.02($2.52)($2.49)($2.86)($1.97)($1.45)($0.58)($9.73)
EPS — diluted($1.10)($0.62)$3.78($2.52)($2.49)($2.86)($1.97)($1.45)($0.58)($9.73)
Shares outstanding — basic (M)14015617017517918318719020617
Shares outstanding — diluted (M)14015618017517918318719020617

Showing the latest 10 of 17 fiscal years.

  • ⚑ Weighted-average shares changed ÷12.50 between FY2024 and FY2025 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.